EXPRESS: Is plasma level of Coenzyme Q10 a predictive marker for left ventricular remodeling after revascularization for ST-segment elevation myocardial infarction ?

BACKGROUND Left ventricular remodeling (LVR) that frequently occurs after acute myocardial infarction (AMI) is associated with an increased risk of heart failure and cardiovascular death. Although several risk factors have been identified, there is still no marker in clinical use to predict LVR. Plasma level of Coenzyme Q10 (CoQ10), that plays a key role in mitochondrial energy production and as an antioxidant, seems to be negatively correlated with left ventricular function after AMI. OBJECTIVE The goal of our study was to determine whether the plasma CoQ10 baseline concentrations at time of the ST-elevation myocardial infarction (STEMI) could predict LVR at 6 months follow-up. METHODS Sixty-eight patients who were admitted to hospital for STEMI and successfully revascularized with primary percutaneous coronary intervention (PPCI) were recruited. All patients underwent a 3D-echocardiography examination within the first 4 days after PPCI and 6 months later then divided in 2 groups based on the presence or not of LVR. Plasma CoQ10 level at the time of PPCI was determined using high performance liquid chromatography-tandem mass spectrometry (HPLC/MSMS). RESULTS While we found similar plasma CoQ10 concentrations compared to other studies, no association was evidenced between CoQ10 levels and LVR (p=0.89). CONCLUSION We found no evidence for using plasma CoQ10 concentration as an early prediction marker of LVR after STEMI.